spacer
home > ebr > autumn 2018 > goal!
PUBLICATIONS
European Biopharmaceutical Review

GOAL!

Alnylam’s Onpattro is the first approved drug that treats disease by RNA interference – silencing gene expression. It is the culmination of a 15-year-long march by the company to develop and harness the enabling technologies necessary for successful commercialisation. Some commentators have called it a “clean sweep of efficacy and safety.”

The FDA views this breakthrough as part of a growing trend to treat disease by targeting root cause instead of treating symptoms. In this regard, RNA interference is complementary to other advanced therapeutic approaches. RNAi, like monoclonal antibodies, is dosedependent and can be modulated. Gene therapy, when it comes to fruition, is, in principle, permanent.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board, a graduate of the Harvard Business School, US, and an industry consultant with experience in the biotech and biopharma industry.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Pioneering a New Era of Cell Therapy Manufacturing

Aug 09 2022: Following its successful inspection, our Memphis cell therapy manufacturing facility is paving the way in the cell and gene therapy industry as the first contract development and manufacturing organization (CDMO) in North America to be awarded a commercial GMP license to produce allogeneic cell therapy drug products from the European Medicines Agency (EMA).
More info >>

White Papers

Igb Tamper Evident Folding Box

IGB

The easiest, safest and less expensive solution in compliance with what requires Dir. 62/2011/EU, FDA and TGA.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement